NTRANTRA
US • —
$271.45
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
+36.6% YoY
Gross Margin
65.1%
Health Score
5/10
D/E Ratio
0.05
Confidence
LOW
Business Snapshot
Natera is a biotechnology company focused on cell-free DNA testing, primarily serving the reproductive health and oncology markets with products such as non-invasive prenatal screening and liquid biopsy tests for cancer detection and monitoring. It operates in the rapidly growing genetic testing and precision oncology markets, where it competes as a challenger to established players like Guardant Health and Exact Sciences, leveraging its proprietary molecular biology and bioinformatics platform. The company is currently unprofitable on a net income basis, with a market cap that falls into the mid-to-large-cap tier, though specific market cap data is unavailable. Gross margins are high at 65.1%, indicating a defensible technology moat and a scalable testing business model that benefits from high fixed-cost leverage as test volumes increase.
Financial Health
Gross margin stands at a robust 65.1%, though prior-year comparison data is unavailable to assess trend direction; net margin is negative at -9.1%, indicating the company is not yet profitable on an operating basis. The balance sheet is exceptionally clean, with a minimal debt-to-equity ratio of 0.05x and a current ratio of 3.39x, reflecting a fortress-level liquidity position with ample current assets to cover near-term obligations...
Risk Assessment
- VALUATION — Price/sales of 15.55x is reflective of a high-growth premium, but with no P/E or DCF anchor available, the stock's current price is priced entirely on future expectations with no fundamental floor.
- EARNINGS QUALITY — Natera has beaten analyst estimates in only 1 of the last 4 quarters, indicating below-average management guidance credibility and forecasting accuracy.
- PROFITABILITY — Net margin of -9.1% and return on equity of -15.1% confirm the company is not profitable, meaning it relies on balance sheet cash or financing to sustain operations while seeking a path to profitability.
- FCF / CASH BURN — Free cash flow is unavailable, so a cash burn rate cannot be quantified, but the combination of negative net income and high capital requirements for testing scale implies the company may be consuming cash rather than generating it.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
Gross margin stands at a robust 65.1%, though prior-year comparison data is unavailable to assess trend direction; net margin is negative at -9.1%, indicating the company is not yet profitable on an operating basis. The balance sheet is exceptionally clean, with a minimal debt-to-equity ratio of 0.05x and a current ratio of 3.39x, reflecting a fortress-level liquidity position with ample current assets to cover near-term obligations. Free cash flow data is unavailable, preventing a direct assessment of cash generation or burn, but the negative net margin and negative return on equity of -15.1% suggest the business is reinvesting heavily and not yet self-funding. Overall, Natera has a low-debt, high-liquidity profile that provides financial flexibility, but the lack of profitability and missing free cash flow data creates uncertainty about the sustainability of its cash runway without future capital raises.
- VALUATION — Price/sales of 15.55x is reflective of a high-growth premium, but with no P/E or DCF anchor available, the stock's current price is priced entirely on future expectations with no fundamental floor. - EARNINGS QUALITY — Natera has beaten analyst estimates in only 1 of the last 4 quarters, indicating below-average management guidance credibility and forecasting accuracy. - PROFITABILITY — Net margin of -9.1% and return on equity of -15.1% confirm the company is not profitable, meaning it relies on balance sheet cash or financing to sustain operations while seeking a path to profitability. - FCF / CASH BURN — Free cash flow is unavailable, so a cash burn rate cannot be quantified, but the combination of negative net income and high capital requirements for testing scale implies the company may be consuming cash rather than generating it. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives